EDAP TMS Reports Outstanding Focal One System Sales
EDAP TMS SA, the pioneer in robotic energy-based therapies, has recently shared impressive preliminary sales results for the fourth quarter of the year. The company recorded sales of 11 Focal One Systems worldwide during this period, signifying a remarkable achievement in their operational performance.
Impressive Growth in U.S. Procedures
The company witnessed unprecedented growth in the U.S. market as well, with a record number of procedures performed using the Focal One technology. This marks a notable year-over-year growth rate of 30%, illustrating the growing acceptance and utilization of this advanced treatment option among healthcare providers. As stated by Ryan Rhodes, Chief Executive Officer of EDAP, this achievement reflects the increasing adoption of the Focal One Robotic HIFU technology platform, which is reshaping how urologists approach the management of prostate cancer.
Transforming Urology Practices
Rhodes highlighted that the rapid increase in the number of Focal One procedures signifies the transformative impact of this technology on urology practices. With the Focal One system becoming a mainstream treatment option, it is essential for practitioners to stay abreast of its benefits and capabilities. The recently published HIFI study in the prestigious journal "European Urology" is expected to further elevate awareness and encourage the adoption of the Focal One technology among urologists.
Strong Outlook for 2025
As EDAP TMS enters the new year, the company is optimistic about the future of the Focal One platform. The pipeline remains robust, and the management anticipates a steady increase in urology practices adopting this innovative treatment for patients diagnosed with prostate cancer. The groundwork laid in the past year positions EDAP to capitalize on market opportunities that can enhance patient outcomes.
Commitment to Advancing Medical Technology
EDAP TMS's dedication to innovation continues to set them apart in the medical field. With advanced robotic energy-based therapies being their primary focus, the company aims to reshape the landscape of minimally invasive treatments for various medical conditions. The introduction of the Focal One system highlights their commitment to providing effective solutions for challenging medical problems.
Future Developments and Expectations
EDAP anticipates completing quarter-end financial reporting processes soon and plans to release finalized results in the following months. Such transparency illuminates the company's trajectory and reaffirms its commitment to its stakeholders.
About EDAP TMS SA
EDAP TMS SA is a renowned leader in the development of robotic energy-based therapies. The company designs, manufactures, and distributes minimally invasive medical devices powered by ultrasound technology. The Focal One system leads to innovative prostate focal therapy guided by urologists, with potential applications extending beyond prostate cancer treatments.
Frequently Asked Questions
What are the key highlights of EDAP's recent sales report?
EDAP reported preliminary record sales of 11 Focal One Systems in Q4, alongside a 30% increase in U.S. procedures compared to the previous year.
How does the Focal One technology impact prostate cancer treatment?
The Focal One system offers a minimally invasive option that changes how urologists treat prostate cancer, making it a leading choice in its field.
What is the significance of the HIFI study for EDAP?
The HIFI study's publication in a prominent journal is expected to enhance awareness and promote wider adoption of the Focal One technology among healthcare professionals.
What is EDAP’s outlook for 2025?
EDAP anticipates continued growth in the adoption of the Focal One system and remains confident in its pipeline of products and innovations for the urology market.
How can investors get in touch with EDAP’s investor relations?
Investors can contact Blandine Confort at EDAP for any inquiries related to investor relations or legal affairs.
